PER® Chemotherapy Foundation Symposium (CFS) | Conference

Multimodal Care Marks the Past, Present, and Future of Localized Breast Cancer Management

November 10th 2023

Improvements in screening, systemic therapy, and precision medicine have reduced breast cancer mortality and morbidity, and further progress will hinge on the use of ctDNA and CTCs for disease monitoring, continued development of novel antiestrogenic agents, and movement of ADCs and immunotherapy into expanded settings and indications.

Dr Scher on the Importance of Molecular Testing in Prostate Cancer

November 10th 2023

Howard I. Scher, MD, discusses the evolution of molecular testing mechanisms in patients with prostate cancer and highlights the importance of making patient-centered decisions based on test results.

Reflecting on Advances Made in High-Risk, Low-Grade Prostate Cancer Management

November 10th 2023

Howard I. Scher, MD, sheds light on various research programs he has led or has been heavily involved with that have helped change the course of prostate cancer treatment over the years.

Dr Jhaveri on the Evolution of Endocrine Therapy in ER+ Metastatic Breast Cancer

November 10th 2023

Komal Jhaveri , MD, FACP, discusses the rationale behind the ongoing clinical development of elacestrant and other endocrine therapies in patients with estrogen receptor–positive metastatic breast cancer.

Enfortumab Vedotin Plus Pembrolizumab Has Potential to Alter SOC in Frontline Urothelial Cancer

November 10th 2023

The combination of enfortumab vedotin-ejfv plus pembrolizumab represents a chemotherapy-free regimen that could alter the standard of care in the frontline treatment of all patients with metastatic urothelial carcinoma.

Dr Braun on the Clinical Implications of the CONTACT-03 Trial in RCC

November 10th 2023

David Braun, MD, PhD, discusses the findings from the phase 3 CONTACT-03 trial investigating immunotherapy rechallenge in patients with renal cell carcinoma and the implications of these findings on the RCC treatment paradigm.

Dr Tremblay on the Identification and Prevalence of MDS/MPN Overlap Syndromes

November 10th 2023

Douglas A. Tremblay, MD, discusses the prevalence of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes and the evolving treatment paradigm for these diseases.

Pursuit of Effective Agents Continues in Multiple Types of Sarcomas

November 10th 2023

Research has continued to focus on developing novel therapies and bringing new treatments to the sarcoma treatment paradigm.

Unique Molecular Profiles of Biliary Tract Cancers Drive Continued Development of Targeted Therapies

November 9th 2023

The mitigation and management of toxicities is a key component of treating patients with biliary tract cancers with targeted therapies.

Dr Markman on Pragmatic Clinical Trial Designs in Ovarian Cancer

November 9th 2023

Maurie Markman, MD, discusses the importance of designing clinical trials for patients with ovarian cancer that are based on real-world data and consider the increasing complexity of treatment sequencing in this disease.

Markman Underscores Unanswered Questions in Ovarian Cancer Management

November 9th 2023

Although advancements were “simple” to track for more than 40 years and left few questions open for evaluation in the ovarian cancer treatment paradigm, new questions have begun to develop surrounding the complexity of care.

Recent Clinical Trial Updates Shift DLBCL Treatment Paradigm

November 9th 2023

Gilles Salles, MD, PhD, expands on how data from recent clinical trials have helped shift the treatment paradigm for patients with diffuse large B-cell lymphoma.

Lamanna Details Evolution of CLL Treatment Following Resistance

November 9th 2023

Nicole Lamanna, MD, discusses treatment options for patients with chronic lymphocytic leukemia who develop resistance to a prior treatment.

Data Continue to Refine Frontline BTK Inhibitor Selection in CLL

November 8th 2023

Along with the combination of venetoclax and obinutuzumab, the BTK inhibitor–based regimens of zanubrutinib monotherapy and acalabrutinib plus obinutuzumab represent the preferred options in the National Comprehensive Cancer Network Guidelines for the first-line treatment of patients with chronic lymphocytic leukemia without 17p deletions or TP53 mutations.

PD-L1 Status Could Help Inform Patient Selection for IO-Based Therapy in HNSCC

December 15th 2022

Ranee Mehra, MD, discusses the significance of 5-year follow-up data and the subgroup analysis from KEYNOTE-048, the benefits and limitations of IO therapy in head and neck squamous cell carcinoma, and research aiming to expand the role of IO combination regimens in this space.

Novel Targeted Immunotherapies Strengthen Frontline Treatment Strategies in Hodgkin Lymphoma

December 15th 2022

Joshua Brody, MD, discusses unmet needs in patient subgroups within Hodgkin lymphoma, recent advancements in the use of antibody-drug conjugates such as brentuximab vedotin and anti–PD-1 therapies in earlier lines of therapy, and future avenues for expanding the use of immunotherapy in this tumor type.

Dr. Brody on Updated Data From the ECHELON-1 Trial in Hodgkin Lymphoma

November 29th 2022

Joshua Brody, MD, discusses key follow-up data from the phase 3 ECHELON-1 trial in classical Hodgkin lymphoma.

Dr. Liu on the Development of Frontline Atezolizumab Combination Therapies in SCLC

November 29th 2022

Stephen V. Liu, MD, discusses efforts to develop atezolizumab-based combination therapies for patients with small cell lung cancer.

Updates from Melanoma Trials Demonstrate New Roles for Adjuvant/Neoadjuvant Treatment

November 23rd 2022

Sapna Patel, MD, reviews several key studies across stages of melanoma and emerging targeted therapies for patients with BRAF mutations.

Clinical Trials Propel New Standards of Care for Thyroid Cancer

November 12th 2022

Alan L. Ho, MD, PhD, discusses targeted therapies such as TKIs that have demonstrated promising efficacy in multiple patient populations as well as the agents lenvatinib and pembrolizumab.